Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism

The cytochrome P450 (CYP) 2C9 R150H (*8) allele occurs commonly in African Americans and is associated with lower warfarin dose requirements. We conducted a pharmacokinetic study to examine whether the CYP2C9*8 allele impacts warfarin clearance in African‐American patients. We also conducted an in vitro kinetic study of S‐warfarin 7‐hydroxylation using complementary DNA (cDNA)‐expressed CYP2C9 enzymes. We observed a 30% reduction in the unbound oral clearance of S‐warfarin and a 25% lower R‐ to S‐warfarin plasma concentration ratio in patients with the CYP2C9*8 allele (n = 12) as compared to CYP2C9*1 homozygotes (n = 26). Consistent with these findings, the in vitro intrinsic clearance of S‐warfarin was 30% lower with the cDNA‐expressed R150H protein as compared to the wild‐type protein. These data show that the R150H variant protein expressed by the CYP2C9*8 allele is associated with lower S‐warfarin clearance. This finding provides clinical and experimental evidence to explain the lower warfarin dose requirements in patients with the CYP2C9*8 allele.

[1]  J. Crawford,et al.  Simplification of drug dosage calculation by application of the surface area principle. , 1950, Pediatrics.

[2]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[3]  William J. Jusko,et al.  Berichten , 2005, Pharmaceutisch weekblad.

[4]  L. Wienkers,et al.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.

[5]  W. Trager,et al.  Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. , 1996, Archives of biochemistry and biophysics.

[6]  C. Crespi,et al.  The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.

[7]  H. Echizen,et al.  Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[8]  H. Echizen,et al.  Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes , 1998, Clinical pharmacology and therapeutics.

[9]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[10]  H. Yamazaki,et al.  Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[11]  Kaoru Kobayashi,et al.  CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.

[12]  R. Kim,et al.  Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. , 2001, Molecular pharmacology.

[13]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[14]  E. Spina,et al.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance , 2002, Clinical pharmacology and therapeutics.

[15]  H. Mohrenweiser,et al.  Discovery of new potentially defective alleles of human CYP2C9. , 2004, Pharmacogenetics.

[16]  U. Yasar,et al.  Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. , 2004, Clinical pharmacology and therapeutics.

[17]  T. Langaee,et al.  Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. , 2004, Clinical chemistry.

[18]  J. Gala,et al.  CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population , 2005, Pharmacogenetics and genomics.

[19]  D. Rock,et al.  CYP2C9 Inhibition: Impact of Probe Selection and Pharmacogenetics on in Vitro Inhibition Profiles , 2006, Drug Metabolism and Disposition.

[20]  Julie A. Johnson,et al.  Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements , 2006, Clinical pharmacology and therapeutics.

[21]  Timothy S Tracy,et al.  Polymorphic Variants of CYP2C9: Mechanisms Involved in Reduced Catalytic Activity , 2007, Molecular Pharmacology.

[22]  G. Mcgwin,et al.  Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African‐American and European‐American Patients on Warfarin , 2008, Clinical pharmacology and therapeutics.

[23]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[24]  J. Lindh,et al.  Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis , 2009, European Journal of Clinical Pharmacology.

[25]  R. Beyth,et al.  Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[26]  C. Thorn,et al.  Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans , 2008, Clinical pharmacology and therapeutics.

[27]  J. Hirsh,et al.  Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[28]  N. Limdi,et al.  Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. , 2008, Pharmacogenomics.

[29]  J. Halperin,et al.  CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. , 2009, Pharmacogenomics.

[30]  T. Miyata,et al.  Substrate-Dependent Functional Alterations of Seven CYP2C9 Variants Found in Japanese Subjects , 2009, Drug Metabolism and Disposition.

[31]  T. Langaee,et al.  Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans , 2010, Clinical pharmacology and therapeutics.

[32]  U. Fuhr,et al.  Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants. , 2010, Current drug metabolism.

[33]  L. Cavallari,et al.  Association of Apolipoprotein E Genotype with Duration of Time to Achieve a Stable Warfarin Dose in African‐American Patients , 2011, Pharmacotherapy.

[34]  A. Krause,et al.  Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. , 2011, Pharmacogenomics.

[35]  D. Nicolae,et al.  The Missing Association: Sequencing‐Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans , 2011, Clinical pharmacology and therapeutics.